Kinetic reconstruction of the cancellous (Cn) and endocortical (Ec) remodelling unit reveals a net positive bone balance (BB) after 12 months of treatment with romosozumab
Erik F. Eriksen,
Rogely W. Boyce,
Yifei Shi,
Jacques P. Brown,
Stéphane Horlait,
Cesar Libanati,
Roland Chapurlat,
Pascale Chavassieux
Affiliations
Erik F. Eriksen
Oslo University Hospital, Department of Endocrinology- Morbid Obesity and Preventive Medicine, Oslo, Norway; Corresponding author.
Rogely W. Boyce
Amgen Inc., Department of Comparative Biology and Safety Sciences, Thousand Oaks- CA, United States
Yifei Shi
Amgen Inc., Global Biostatistical Science, Thousand Oaks- CA, United States
Jacques P. Brown
CHU de Quebec Research Centre and Laval University, Department of Medicine, Quebec, Canada
Stéphane Horlait
Amgen Inc., Bone Medical Strategy, Boulogne Billancourt, France
Cesar Libanati
UCB Pharma, Bone Medical Strategy, Brussels, Belgium
Roland Chapurlat
INSERM UMR 1033- Université de Lyon, Bone and Chronic Diseases, Lyon, France
Pascale Chavassieux
INSERM UMR 1033- Université de Lyon, Bone and Chronic Diseases, Lyon, France
